Jack Chung, Carmen C W Lim, Daniel Stjepanović, Wayne Hall, Jason P Connor, Gary C K Chan
{"title":"青少年吸食大麻趋势（2021-2023）：德尔塔-9-四氢大麻酚、大麻二酚和合成大麻素。","authors":"Jack Chung, Carmen C W Lim, Daniel Stjepanović, Wayne Hall, Jason P Connor, Gary C K Chan","doi":"10.1016/j.amepre.2025.107655","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>This study tracks national prevalence trends in the vaping of different cannabinoids among U.S. youths. Current (past 30-day) adolescent vaping prevalence of delta-9-tetrahydrocannabinol, cannabidiol, and synthetic cannabinoids from 2021 to 2023 was estimated.</p><p><strong>Methods: </strong>Data came from 3 National Youth Tobacco Survey waves for the years 2021 (n=20,128), 2022 (n=27,965), and 2023 (n=21,806), comprising a total of 69,899 U.S. middle- and high-school students (aged 11-18 years). The population estimates and the weighted prevalence of current adolescent vaping of delta-9-tetrahydrocannabinol, cannabidiol, and synthetic cannabinoids were estimated by survey year and separately by age and biological sex. Analyses were conducted in 2024.</p><p><strong>Results: </strong>There was a significant increase in adolescent vaping of delta-9-tetrahydrocannabinol, cannabidiol, and synthetic cannabinoids from 2021 to 2023. Delta-9-tetrahydrocannabinol vaping peaked in 2022, whereas the use of synthetic cannabinoids continued to increase. It is estimated that 7.4% (or 2.55 million) of U.S. adolescents were currently vaping delta-9-tetrahydrocannabinol, whereas 2.9% (or 999,000) were vaping cannabidiol, and 1.8% (or 620,000) were vaping synthetic cannabinoids in 2023. Notably, the prevalence of delta-9-tetrahydrocannabinol, cannabidiol, and synthetic cannabinoids vaping was higher among females than among males in 2023, where prevalence of both delta-9-tetrahydrocannabinol and synthetic cannabinoids vaping among those aged 11-13 years doubled between 2021 and 2023. In addition, uncertain respondents answering don't know whether they had vaped synthetic cannabinoids, tripled across the years.</p><p><strong>Conclusions: </strong>This study reveals that vaping of delta-9-tetrahydrocannabinol, cannabidiol, and synthetic cannabinoids has increased among U.S. adolescents from 2021 to 2023. Further research is essential to understand the nature of adolescent cannabis vaping and its implications on youth health.</p>","PeriodicalId":50805,"journal":{"name":"American Journal of Preventive Medicine","volume":" ","pages":"107655"},"PeriodicalIF":4.3000,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Adolescent Cannabis Vaping Trends (2021-2023): Delta-9-Tetrahydrocannabinol, Cannabidiol, and Synthetic Cannabinoids.\",\"authors\":\"Jack Chung, Carmen C W Lim, Daniel Stjepanović, Wayne Hall, Jason P Connor, Gary C K Chan\",\"doi\":\"10.1016/j.amepre.2025.107655\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>This study tracks national prevalence trends in the vaping of different cannabinoids among U.S. youths. Current (past 30-day) adolescent vaping prevalence of delta-9-tetrahydrocannabinol, cannabidiol, and synthetic cannabinoids from 2021 to 2023 was estimated.</p><p><strong>Methods: </strong>Data came from 3 National Youth Tobacco Survey waves for the years 2021 (n=20,128), 2022 (n=27,965), and 2023 (n=21,806), comprising a total of 69,899 U.S. middle- and high-school students (aged 11-18 years). The population estimates and the weighted prevalence of current adolescent vaping of delta-9-tetrahydrocannabinol, cannabidiol, and synthetic cannabinoids were estimated by survey year and separately by age and biological sex. Analyses were conducted in 2024.</p><p><strong>Results: </strong>There was a significant increase in adolescent vaping of delta-9-tetrahydrocannabinol, cannabidiol, and synthetic cannabinoids from 2021 to 2023. Delta-9-tetrahydrocannabinol vaping peaked in 2022, whereas the use of synthetic cannabinoids continued to increase. It is estimated that 7.4% (or 2.55 million) of U.S. adolescents were currently vaping delta-9-tetrahydrocannabinol, whereas 2.9% (or 999,000) were vaping cannabidiol, and 1.8% (or 620,000) were vaping synthetic cannabinoids in 2023. Notably, the prevalence of delta-9-tetrahydrocannabinol, cannabidiol, and synthetic cannabinoids vaping was higher among females than among males in 2023, where prevalence of both delta-9-tetrahydrocannabinol and synthetic cannabinoids vaping among those aged 11-13 years doubled between 2021 and 2023. In addition, uncertain respondents answering don't know whether they had vaped synthetic cannabinoids, tripled across the years.</p><p><strong>Conclusions: </strong>This study reveals that vaping of delta-9-tetrahydrocannabinol, cannabidiol, and synthetic cannabinoids has increased among U.S. adolescents from 2021 to 2023. Further research is essential to understand the nature of adolescent cannabis vaping and its implications on youth health.</p>\",\"PeriodicalId\":50805,\"journal\":{\"name\":\"American Journal of Preventive Medicine\",\"volume\":\" \",\"pages\":\"107655\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2025-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Preventive Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.amepre.2025.107655\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Preventive Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.amepre.2025.107655","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Adolescent Cannabis Vaping Trends (2021-2023): Delta-9-Tetrahydrocannabinol, Cannabidiol, and Synthetic Cannabinoids.
Introduction: This study tracks national prevalence trends in the vaping of different cannabinoids among U.S. youths. Current (past 30-day) adolescent vaping prevalence of delta-9-tetrahydrocannabinol, cannabidiol, and synthetic cannabinoids from 2021 to 2023 was estimated.
Methods: Data came from 3 National Youth Tobacco Survey waves for the years 2021 (n=20,128), 2022 (n=27,965), and 2023 (n=21,806), comprising a total of 69,899 U.S. middle- and high-school students (aged 11-18 years). The population estimates and the weighted prevalence of current adolescent vaping of delta-9-tetrahydrocannabinol, cannabidiol, and synthetic cannabinoids were estimated by survey year and separately by age and biological sex. Analyses were conducted in 2024.
Results: There was a significant increase in adolescent vaping of delta-9-tetrahydrocannabinol, cannabidiol, and synthetic cannabinoids from 2021 to 2023. Delta-9-tetrahydrocannabinol vaping peaked in 2022, whereas the use of synthetic cannabinoids continued to increase. It is estimated that 7.4% (or 2.55 million) of U.S. adolescents were currently vaping delta-9-tetrahydrocannabinol, whereas 2.9% (or 999,000) were vaping cannabidiol, and 1.8% (or 620,000) were vaping synthetic cannabinoids in 2023. Notably, the prevalence of delta-9-tetrahydrocannabinol, cannabidiol, and synthetic cannabinoids vaping was higher among females than among males in 2023, where prevalence of both delta-9-tetrahydrocannabinol and synthetic cannabinoids vaping among those aged 11-13 years doubled between 2021 and 2023. In addition, uncertain respondents answering don't know whether they had vaped synthetic cannabinoids, tripled across the years.
Conclusions: This study reveals that vaping of delta-9-tetrahydrocannabinol, cannabidiol, and synthetic cannabinoids has increased among U.S. adolescents from 2021 to 2023. Further research is essential to understand the nature of adolescent cannabis vaping and its implications on youth health.
期刊介绍：
The American Journal of Preventive Medicine is the official journal of the American College of Preventive Medicine and the Association for Prevention Teaching and Research. It publishes articles in the areas of prevention research, teaching, practice and policy. Original research is published on interventions aimed at the prevention of chronic and acute disease and the promotion of individual and community health.
Of particular emphasis are papers that address the primary and secondary prevention of important clinical, behavioral and public health issues such as injury and violence, infectious disease, women''s health, smoking, sedentary behaviors and physical activity, nutrition, diabetes, obesity, and substance use disorders. Papers also address educational initiatives aimed at improving the ability of health professionals to provide effective clinical prevention and public health services. Papers on health services research pertinent to prevention and public health are also published. The journal also publishes official policy statements from the two co-sponsoring organizations, review articles, media reviews, and editorials. Finally, the journal periodically publishes supplements and special theme issues devoted to areas of current interest to the prevention community.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
